IL221665A - R – n– (3–3–) 7 – Methyl – 1 h– Indazole – 5 – Ile) –1– (4– (1 – Methylphipridine – 4 – Ile) Phiprazine – L – Ile) 1-Oxopropane-2-Ile ) -4- (2-oxo-1,2-dihydroquinoline-3-yl) piperidine-1-carboxamide, its own pharmaceutical product - Google Patents

R – n– (3–3–) 7 – Methyl – 1 h– Indazole – 5 – Ile) –1– (4– (1 – Methylphipridine – 4 – Ile) Phiprazine – L – Ile) 1-Oxopropane-2-Ile ) -4- (2-oxo-1,2-dihydroquinoline-3-yl) piperidine-1-carboxamide, its own pharmaceutical product

Info

Publication number
IL221665A
IL221665A IL221665A IL22166512A IL221665A IL 221665 A IL221665 A IL 221665A IL 221665 A IL221665 A IL 221665A IL 22166512 A IL22166512 A IL 22166512A IL 221665 A IL221665 A IL 221665A
Authority
IL
Israel
Prior art keywords
oxopropan
dihydroquinolin
indazol
methylpiperidin
piperazin
Prior art date
Application number
IL221665A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL221665(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL221665A publication Critical patent/IL221665A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL221665A 2010-03-30 2012-08-27 R – n– (3–3–) 7 – Methyl – 1 h– Indazole – 5 – Ile) –1– (4– (1 – Methylphipridine – 4 – Ile) Phiprazine – L – Ile) 1-Oxopropane-2-Ile ) -4- (2-oxo-1,2-dihydroquinoline-3-yl) piperidine-1-carboxamide, its own pharmaceutical product IL221665A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31901510P 2010-03-30 2010-03-30
PCT/US2011/028168 WO2011123232A1 (en) 2010-03-30 2011-03-11 Cgrp receptor antagonist

Publications (1)

Publication Number Publication Date
IL221665A true IL221665A (en) 2016-07-31

Family

ID=43896902

Family Applications (1)

Application Number Title Priority Date Filing Date
IL221665A IL221665A (en) 2010-03-30 2012-08-27 R – n– (3–3–) 7 – Methyl – 1 h– Indazole – 5 – Ile) –1– (4– (1 – Methylphipridine – 4 – Ile) Phiprazine – L – Ile) 1-Oxopropane-2-Ile ) -4- (2-oxo-1,2-dihydroquinoline-3-yl) piperidine-1-carboxamide, its own pharmaceutical product

Country Status (29)

Country Link
US (1) US8481546B2 (enExample)
EP (1) EP2552906B1 (enExample)
JP (1) JP5908455B2 (enExample)
KR (3) KR20180049168A (enExample)
CN (1) CN102834388B (enExample)
AR (1) AR080746A1 (enExample)
AU (1) AU2011233627B2 (enExample)
BR (1) BR112012024785B1 (enExample)
CA (1) CA2794950C (enExample)
CL (1) CL2012002739A1 (enExample)
CY (1) CY1117593T1 (enExample)
DK (1) DK2552906T3 (enExample)
EA (1) EA022815B1 (enExample)
ES (1) ES2562610T3 (enExample)
HR (1) HRP20160287T1 (enExample)
HU (1) HUE028735T2 (enExample)
IL (1) IL221665A (enExample)
MX (1) MX2012010725A (enExample)
NZ (1) NZ603231A (enExample)
PE (1) PE20130340A1 (enExample)
PL (1) PL2552906T3 (enExample)
PT (1) PT2552906E (enExample)
RS (1) RS54608B1 (enExample)
SG (1) SG183918A1 (enExample)
SI (1) SI2552906T1 (enExample)
SM (1) SMT201600078B (enExample)
TW (1) TWI483937B (enExample)
WO (1) WO2011123232A1 (enExample)
ZA (1) ZA201207292B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2020077038A1 (en) * 2018-10-13 2020-04-16 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of cgrp antagonists
KR20210116560A (ko) * 2019-01-20 2021-09-27 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 편두통 돌발을 치료하기 위한 cgrp 길항제
SG11202111251SA (en) 2019-04-11 2021-11-29 R P Scherer Technologies Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN114980862A (zh) * 2019-12-17 2022-08-30 拜尔哈文制药股份有限公司 Cgrp抑制剂的鼻内药物组合物
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
CA3202137A1 (en) * 2020-11-19 2022-05-27 Pfizer Ireland Pharmaceuticals Compositions for improved delivery of cgrp inhibitors
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2022217008A1 (en) 2021-04-09 2022-10-13 Teva Czech Industries S.R.O Solid state forms of zavegepant and process for preparation thereof
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
US20240366618A1 (en) * 2021-10-11 2024-11-07 Pfizer Ireland Pharmaceuticals CGRP Antagonists for Treating Trigeminal Neuralgia
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途
US20250276959A1 (en) 2022-11-09 2025-09-04 Teva Czech Industries S.R.O. Solid state forms of zavegepant hydrochloride and process for preparation thereof
CN116003387B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
JP2026515029A (ja) 2023-04-28 2026-05-13 成都思倍博医▲薬▼科技有限公司 オキソピリド脂肪族環又は脂肪族複素環構造を含む化合物及びその医学的使用
WO2025003905A1 (en) 2023-06-29 2025-01-02 Pfizer Inc. Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
CN119462607B (zh) * 2023-08-10 2025-11-28 南京宁丹新药技术股份有限公司 一类喹啉酮衍生物及其用途
EP4781986A1 (en) 2023-09-21 2026-07-29 Sichuan Purity Pharmaceutical Co., Ltd. Pharmaceutical composition having improved pharmacokinetic properties
CN117551081A (zh) * 2023-11-13 2024-02-13 北京康立生医药技术开发有限公司 一种偏头痛治疗药物新的制备方法
ES3027457A1 (es) * 2023-12-13 2025-06-13 Moehs Iberica Sl Metodo de preparacion de zavegepant, intermedios de sintesis de zavegepant y metodos de preparacion de los mismos
IT202400011158A1 (it) 2024-05-16 2025-11-16 Olon Spa Processo per preparare (r)-2-ammino-3-(7-metil-1h-indazol-5-il) propanoato di metile, e suo uso come intermedio per la sintesi di zavegepant.
WO2026033478A1 (en) 2024-08-09 2026-02-12 Olon S.P.A. Process for preparing 3-piperidin-4-il-1h- quinolin-2-one or a salt thereof and its use as an intermediate for the preparation of pharmaceutical active ingredients antagonists of the cgrp peptide receptor
CN119306698B (zh) * 2024-10-09 2025-10-21 浙江工业大学 一种制备扎维吉泮中间体的新方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
ES2616539T3 (es) * 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
EP1722792A1 (de) 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
CN101495480B (zh) * 2006-05-03 2013-07-10 百时美施贵宝公司 作为降钙素基因相关肽受体拮抗剂的受限化合物
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor

Also Published As

Publication number Publication date
US20120059017A1 (en) 2012-03-08
ZA201207292B (en) 2014-03-26
CA2794950C (en) 2017-09-26
HUE028735T2 (en) 2017-01-30
KR20180049168A (ko) 2018-05-10
TW201139414A (en) 2011-11-16
SI2552906T1 (sl) 2016-05-31
HK1174914A1 (zh) 2013-06-21
US8481546B2 (en) 2013-07-09
ES2562610T3 (es) 2016-03-07
AR080746A1 (es) 2012-05-02
KR101854249B1 (ko) 2018-05-03
CL2012002739A1 (es) 2013-03-22
SG183918A1 (en) 2012-10-30
WO2011123232A1 (en) 2011-10-06
PL2552906T3 (pl) 2016-06-30
TWI483937B (zh) 2015-05-11
AU2011233627A1 (en) 2012-11-15
KR20130076807A (ko) 2013-07-08
BR112012024785A2 (pt) 2016-06-07
BR112012024785A8 (pt) 2017-10-17
AU2011233627B2 (en) 2013-09-12
SMT201600078B (it) 2016-04-29
MX2012010725A (es) 2012-10-05
HRP20160287T1 (hr) 2016-04-08
JP5908455B2 (ja) 2016-04-26
EA201270751A1 (ru) 2013-02-28
BR112012024785B1 (pt) 2020-12-01
PT2552906E (pt) 2016-03-18
EP2552906B1 (en) 2016-01-06
KR20170068615A (ko) 2017-06-19
NZ603231A (en) 2014-02-28
RS54608B1 (sr) 2016-08-31
CA2794950A1 (en) 2011-10-06
CY1117593T1 (el) 2017-06-28
CN102834388B (zh) 2014-07-16
KR101747477B1 (ko) 2017-06-14
CN102834388A (zh) 2012-12-19
PE20130340A1 (es) 2013-03-30
EP2552906A1 (en) 2013-02-06
JP2013523733A (ja) 2013-06-17
DK2552906T3 (en) 2016-03-29
EA022815B1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
IL283276A (en) Preparations containing 3-(6-(1-(2,2-difluorobenzo[1,3][d]dioxol-5-yl)cycloproponecarboxamide)-3-methylpyridin-2-yl)benzoic acid and n-(5-hydroxy- 2,4-ditert-butyl-phenyl)-4-oxo-h1-quinoline-3-carboxamide and their uses
IL255097A0 (en) Antimicrobial compounds, pharmaceutical preparations containing them and their uses
IL216132A (en) Heterocyclic carboxamide diamine compounds, their uses and their medicinal products and inhibitors
IL222878A (en) N - ((2-oxo-2,1-dihydropyridine-3-ram) methyl) -1h-indole-4-carboxamide and pharmaceuticals containing them
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
ZA201108697B (en) Quinoline derivatives-containing pharmaceutical composition
IL215799A (en) Quinazolone compounds, pharmaceuticals containing them and their uses
IL220863A (en) Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses
IL222314A (en) Acidic Pharmaceuticals 3 - (6 - (1 - (2,2 - Diploorobenzo [d] [1,3] Dioxox - 5 - mo (Cyclopropanecarboxamido) - 3 - Methylpyridine - 2 - mo) Benzoic
PL3492069T3 (pl) Kompozycje farmaceutyczne zawierające tlenowodorotlenek żelaza
IL220154A (en) Annotations 2– (aryl / heteroaryl) –6– (morpholine – 4 – yl) –pyrimidine and their pharmaceutical preparations
IL205742A (en) 4 - (4-Cyano-2-Theoaryl) dihydropyrimidinones, their preparation processes, medications containing them and their use
ZA201200367B (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
IL217927A (en) Azahetrocyclic compounds and their containing pharmaceutical preparations
IL216113A (en) Processed derivatives of indazole and azaza-indazole, pharmaceutical preparations containing them and their uses
PL2542224T3 (pl) Doustna kompozycja farmaceutyczna zawierająca eteksylan dabigatranu
EP2447253A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL209329A0 (en) A pharmaceutical composition comprising rebamipide
IL218937A0 (en) Pharmaceutical compositions comprising rivaroxaban
PL2358702T3 (pl) Związki piperydynowe, zawierająca je kompozycja farmaceutyczna oraz ich zastosowanie
SI2448927T1 (sl) Novi (6-okso-1,6-dihidro-pirimidin-2-il)-amidni derivati, njihova priprava in njihova farmacevtska uporaba kot AKT fosforilacijski inhibitorji
SI2240487T1 (sl) Triazolopiridazini kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
AP2013006768A0 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-fenylsulfanyl)phenyl] piperazine
SMT201500069B (it) Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide
SI2864291T1 (sl) N-(4-(kinolin-4-iloksi)cikloheksil(metil))(hetero)arilkarboksamidi kot antagonisti receptorja androgena, njihova izdelava in uporaba kot medicinski izdelki

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed